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Severe Respiratory and Skeletal Muscles Involvement in a Carrier
of Dysferlinopathy With Chronic Obstructive Pulmonary Disease
Salvatore Fuschillo MD, Yvan Torrente MD, and Giovanni Balzano MD
The natural course of progressive neuromuscular diseases can be complicated by respiratory mus-
cle involvement. In muscular dystrophies such as Duchenne muscular dystrophy and myotonic
dystrophy, respiratory muscle involvement is common. In others such as Becker, limb-girdle, and
facioscapulo-humeral dystrophies, respiratory muscle involvement is infrequent and generally oc-
curs in the more severe cases. Recently, it was reported that a mutation in the dysferlin gene and/or
dysferlin deficiency causes proximal and distal forms of muscular dystrophy, which are known by
the term dysferlinopathy. We describe a case of severe weakness of both limb-girdle and respiratory
muscles in a patient who was carrier of the dysferlin gene mutation and who also had COPD. We
suggest that the systemic inflammatory response of COPD and the dysferlin deficit interact and are
responsible for both the skeletal and respiratory muscle impairment. Key words: chronic obstructive
pulmonary disease; respiratory failure; muscular dystrophy; dysferlin; dysferlinopathy. [Respir Care
2010;55(8):1091–1093. © 2010 Daedalus Enterprises]
Introduction
Muscular dystrophies are a group of progressive, genet-
ically determined, primary degenerative myopathies char-
acterized by different degrees and distributions of muscle
wasting and weakness.1
In many muscular dystrophies such as Duchenne mus-
cular dystrophy and myotonic dystrophy, respiratory mus-
cle involvement is common. In others such as Becker,
limb-girdle, and facioscapulo-humeral dystrophies, respi-
ratory muscle involvement is infrequent and generally oc-
curs in the more severe cases.2
Chronic respiratory failure is an important contributor
to morbidity and mortality in progressive neuromuscular
disorders,2 and these patients often experience acute respi-
ratory failure requiring endotracheal intubation or trache-
ostomy and mechanical ventilation.3
Recently, dysferlin was identified as the member of a
putative muscle-specific repair complex that permits rapid
resealing of membranes disrupted by mechanical stress.4
A mutation in the dysferlin gene and/or dysferlin deficiency
causes proximal and distal muscular dystrophies designated
as limb-girdle muscular dystrophy type 2B, Miyoshi myop-
athy, and anterior-compartment myopathy, which are known
by the term dysferlinopathy.5 One unclear feature of dys-
ferlinopathy is the heterogeneity of clinical presentation: the
same mutation underlies all the clinical presentations in the
same pedigree, and the same clinical presentation can be
caused by different kinds of mutations.6
Inheritance of dysferlinopathy is autosomal recessive,
and the onset of disease is usually late in the first decade,
but may be in the second or third decade or even in middle
age.7,8 Some evidence indicates that inflammation contrib-
utes to muscle pathology in dysferlinopathy.9
Up to now, several studies have reported a prominent
muscle inflammatory response in dysferlinopathy patients.
In fact, in an animal model of dysferlin deficiency (the
mutant mouse strain called SJL), the disease process was
initially considered an “inflammatory” form of muscular
dystrophy. Inflammatory changes have been also observed
in the skeletal muscles of patients with COPD.10
We describe marked impairment of both skeletal and
respiratory muscles in a patient who is a carrier of a het-
erozygous mutation in the dysferlin gene and also has
COPD.
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Case Report
In July 2006 a 70-year-old white man was admitted to
our institution’s pulmonary rehabilitation program because
of COPD. His medical history was remarkable for long-
standing productive cough and a 3-year history of
exercise-induced dyspnea. He had a 30-pack-year history
of cigarette smoking but had stopped smoking a few years
prior to admission. Ten years prior to this presentation he
was diagnosed as having COPD. Two years later he no-
ticed a slowly progressive weakness of the pelvic and
shoulder girdle muscles.
His family history was positive for neuromuscular dis-
ease. He was married to his first cousin, and was the father
of a child affected by Miyoshi myopathy. His recent med-
ical history included 2 admissions to the intensive care unit
because of 2 episodes of hypercapnic acute respiratory fail-
ure: the first in April 2006, the second in May 2006.
On admission he complained about dyspnea on exer-
cise, weakness, and easy fatigability of the muscles of the
shoulder and pelvic girdles.
Physical examination found symmetrical atrophy in the
shoulder and pelvic girdle muscles, hyperlordosis, and
marked kyphosis. He was hindered when raising his arms,
running, and climbing stairs. Gowers sign was positive.
Manual muscle testing revealed 3/5 and 2/5 in the left and
right triceps, respectively, and 2/5 and 3/5 in the left and
right iliopsoas, respectively. His nutritional status, as as-
sessed by body mass index (kg/m2), was 24. In the supine
position his abdominal wall retracted paradoxically during
the inspiratory phase.
A radiograph showed elevation of both hemidiaphragms
during maximal inspiration. Bilateral paresis of the dia-
phragm was confirmed fluoroscopically. There were no
abnormal electrocardiographic findings. A previous mus-
cular biopsy obtained in another hospital showed muscular
fibers ranging from 8 m to 48 m in diameter, and was
conclusive for a non-evolutive myopathy.
Dystrofin, -sarcoglican, and calpain-3 immunoblot
were all normal for quantity and molecular weight. His
dysferlin had a normal molecular weight, but his dysferlin
concentration was only 50% of normal. Genetic analysis
showed a heterozygous mutation in exon 55. Electromyo-
graphy showed a myopathic pattern. A venous blood sam-
ple taken during fasting showed serum creatine phosphoki-
nase, C-reactive protein, and fibrinogen values of 560 U/L
(range 24–190), 3.5 mg/dL (range 0–1), and 555 mg/dL
(range 200–400), respectively.
Spirometry was performed according to the American
Thoracic Society recommendations. Respiratory muscle
strength was assessed via multiple measurements of the
maximum inspiratory pressure and maximum expiratory
pressure at the mouth, generated against an occluded air-
way. PaO2, PaCO2, and pH were measured with the patient
sitting and breathing room air for at least 30 min. Table 1
shows the pulmonary function test and blood gas results.
Static lung volumes were determined via the helium-
dilution method. His vital capacity was 2,240 mL (73% of
predicted) in the sitting position, and decreased to 1,950 mL
(64% of predicted) in the supine position. A nocturnal poly-
somnogram showed an apnea/hypopnea index of 26.2 epi-
sodes per hour (with apnea defined as absence of air flow for
 10 s, and hypopnea defined as a  30% decrease in air
flow associated with a  4% decrease in SpO2).
To relieve airway obstruction, domiciliary inhaled bron-
chodilator was integrated with a 2-week course of oral
prednisone (25 mg/d), after which we instituted nocturnal
intermittent noninvasive ventilation (NIV) to prevent noc-
turnal hypoventilation and desaturations.
The prednisone substantially improved both spirometry
and blood gases (see Table 1). Nocturnal oxyhemoglobin
saturation was monitored with a pulse oximeter with a
finger probe. On NIV his mean nocturnal SpO2 increased
from 91% to 95%, and the percent of sleep time with SpO2
 90% fell from 24% to 2%. After 2 weeks of nocturnal
Table 1. Pulmonary Function Test and Blood Gas Results
Baseline After Steroid Therapy After NIV At 2-Year Follow-up
FVC (mL) 1,890 (63% predicted) 2,620 (88% predicted) ND 2,350 (79% predicted)
FEV1 (mL) 850 (36%) 1,480 (64% predicted) ND 1,080 (47% predicted)
FEV1/FVC (% predicted) 45 56 ND 46
MIP (cm H2O) 37 ND ND 65
MEP (cm H2O) 22 ND ND 28
pH 7.37 7.44 7.42 7.39
PaCO2 (mm Hg) 59 52 45 43
PaO2 (mm Hg) 58 71 86 80
NIV  noninvasive ventilation
FVC  forced vital capacity
ND  no data collected
MIP  maximum inspiratory pressure
MEP  maximum expiratory pressure
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NIV his blood gases further improved, to pH 7.42, PaCO2
45 mm Hg, and PaO2 86 mm Hg.
At a follow-up 2 years later he had satisfactory venti-
lation (see Table 1), his clinical condition was stable, he
reported no further episodes of acute respiratory failure,
and he no longer had exercise-induced dyspnea; exercise
limitation was due mostly to limb weakness.
Discussion
Pulmonary involvement is frequent in neuromuscular
diseases. The severity of pulmonary impairment and the
disease stage at which it develops differ in the different
types of neuromuscular disease.7
Stu¨bgen et al reported that mild dyspnea on exertion,
chronic cough, and recurrent respiratory-tract infections
occur in patients with limb-girdle muscular dystrophies.7
In that study respiratory muscle weakness was common
but mild, and the diaphragm was not disproportionately
affected by the dystrophic process, compared to the limb
muscles.7
In a study that included 60 patients with limb-girdle
muscular dystrophies, there were only minimal changes in
respiratory function and no evidence of respiratory hy-
poventilation, even in the patients who were not more
ambulatory.8 In several other patients with limb girdle
muscular dystrophies, mild pulmonary abnormalities were
reported, but there were substantial blood-gas abnormali-
ties in only 3 patients, who were already wheelchair-bound.2
Differently from the above reports, our patient had severe
diaphragm impairment, respiratory hypoventilation, and
substantial blood-gas abnormalities while he was still am-
bulatory. To the best of our knowledge, among the limb-
girdle muscular dystrophies, no respiratory dysfunction in
dysferlinopathies have been reported.
Recently, clinical symptoms of skeletal muscle weak-
ness were reported in 2 dysferlin-gene-mutation carriers,11
but in those patients no respiratory muscle impairment was
described.11 Our patient had severe weakness of both skel-
etal (shoulder and pelvic girdles) and respiratory muscles,
but no treatment, nutritional state, or electrolyte abnormal-
ities explained that muscle impairment. Based on the tim-
ing of onset of his skeletal muscle impairment and COPD,
it is tempting to hypothesize that systemic inflammatory
response related to the COPD and the genetic dysferlin
deficit interacted to create the respiratory and limb-girdle
muscles weakness.
Patients with respiratory muscle weakness are at risk of
respiratory failure during sleep, especially rapid-eye-
movement sleep.12 In patients with bilateral diaphragm
paralysis the intercostals and accessory muscles become
the principal muscles of inspiration. Inhibition of those
muscles’ activities during rapid-eye-movement sleep
causes severe hypoventilation, apneas, and hypoxia.12
Later, nocturnal hypoxemia and hypercapnia may persist
even during the daytime.
Our patient’s arterial blood gases substantially improved
after relieving the airway obstruction, but they normalized
only after NIV treatment. In previous reports, satisfactory
ventilation was maintained for more than 2 years, with
NIV administered only during sleep.
Surprisingly, at a 2-year follow-up our patient’s maxi-
mum inspiratory pressure had significantly increased above
baseline, in contrast to what we would expect as a conse-
quence of the unloading effect of NIV. A possible expla-
nation is that the dysferlin deficit injures respiratory mus-
cles, which are loaded by the airway obstruction, so NIV
might have rested the fatigued respiratory muscles, which
could have reduced their damage and weakness.
This case of respiratory muscle impairment in a patient
with a dysferlinopathy underscores the importance of as-
sessing pulmonary function both awake and asleep in pa-
tients affected by neuromuscular diseases. We suggest that
COPD (possibly through its systemic inflammatory re-
sponse) can influence the phenotypic expression of dys-
ferlin deficiency.
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